WHO approves Bavarian Nordic's mpox vaccine for adolescents

The World Health Organization said on Monday it had approved Bavarian Nordic's (BAVA.CO), opens new tab mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the disease that has triggered global concern.